Hilde Van Campenhout
About Hilde Van Campenhout
Hilde Van Campenhout is a Senior HEOR Manager at Bristol-Myers Squibb with extensive experience in health economics and outcomes research.
Current Role at Bristol-Myers Squibb
Hilde Van Campenhout is currently serving as the Senior HEOR Manager at Bristol-Myers Squibb in Braine l'Alleud. She holds a significant role in the company's health economics and outcomes research efforts. Her responsibilities include applying her expertise to support payer value information in both the development and post-launch phases of products.
Career at Pfizer
Hilde Van Campenhout had an extensive career at Pfizer from 1998 to 2013. She started as a Clinical Research Associate and then advanced to various roles, including Senior Clinical Research Associate, Clinical Research Manager, Outcomes Research Manager, and ultimately Health Economist and Outcomes Research Manager. During her tenure, she developed a strong foundation in clinical research, health economics, and outcomes research, contributing to numerous projects and studies.
Previous Experience at Novartis
Between 2013 and 2015, Hilde Van Campenhout worked at Novartis as a Market Access Manager in Vilvoorde. In this role, she was responsible for the strategic aspects of market access, facilitating the entry of healthcare products into the market by addressing payer and reimbursement requirements.
Educational Background
Hilde Van Campenhout has an extensive educational background in the medical and health economics fields. She earned her PhD in Medical Sciences and her Master's degrees in Biomedical Engineering Techniques and Biology from KU Leuven. Additionally, she completed a Master's degree in Health Economics from Vlekho. Her academic training underpins her expertise in scientific writing, health economics, and outcomes research.
Skills and Expertise
Hilde Van Campenhout is known for her strong organizational skills, priority setting, and result-oriented approach. She has a comprehensive understanding of health economics and health outcomes research. Her expertise includes the customization and adaptation of health-economic models, project management, and conducting Late Phase studies, such as Observational studies and Phase IIIb studies. Furthermore, she possesses good knowledge of ICH and GCP guidelines, ensuring compliance in pharmaceutical research.